Prognostic implications of reproductive and lifestyle factors in ovarian cancer

Ferlay, 2013, GLOBOCAN 2012 v1.0, No. 11 American Cancer Society, 2016 Cannistra, 2004, Cancer of the ovary, N. Engl. J. Med., 351, 2519, 10.1056/NEJMra041842 McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med., 334, 1, 10.1056/NEJM199601043340101 Ozols, 2003, Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit, J. Clin. Oncol., 21, 2451, 10.1200/JCO.2003.03.039 Cress, 2015, Characteristics of long-term survivors of epithelial ovarian cancer, Obstet. Gynecol., 126, 491, 10.1097/AOG.0000000000000981 Kim, 2014, Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis, Br. J. Cancer, 110, 1878, 10.1038/bjc.2014.29 Konstantinopoulos, 2008, Gene-expression profiling in epithelial ovarian cancer, Nat Clin Pract Oncol., 5, 577, 10.1038/ncponc1178 Bowtell, 2015, Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer, Nat. Rev. Cancer, 15, 668, 10.1038/nrc4019 Prat, 2005, Hereditary ovarian cancer, Hum. Pathol., 36, 861, 10.1016/j.humpath.2005.06.006 Bolton, 2012, Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer, JAMA, 307, 382, 10.1001/jama.2012.20 Tan, 2008, “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations, J. Clin. Oncol., 26, 5530, 10.1200/JCO.2008.16.1703 Fong, 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers, N. Engl. J. Med., 361, 123, 10.1056/NEJMoa0900212 McLaughlin, 2013, Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2, J. Natl. Cancer Inst., 105, 141, 10.1093/jnci/djs494 Candido-dos-Reis, 2015, For E, kConFab I, Australian Ovarian Cancer Study G. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer, Clin. Cancer Res., 21, 652, 10.1158/1078-0432.CCR-14-2497 Møller, 2015, Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database, Gut, 10.1136/gutjnl-2015-309675 Grindedal, 2010, Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds, J. Med. Genet., 47, 99, 10.1136/jmg.2009.068130 Fink, 1996, The role of DNA mismatch repair in platinum drug resistance, Cancer Res., 56, 4881 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Winham, 2016, Investigation of exomic variants associated with overall survival in ovarian cancer, Cancer Epidemiol. Biomark. Prev., 25, 446, 10.1158/1055-9965.EPI-15-0240 Johnatty, 2015, Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium, Clin. Cancer Res., 21, 5264, 10.1158/1078-0432.CCR-15-0632 Thigpen, 1993, Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience, Cancer, 71, 606 Bristow, 2013, Disparities in ovarian cancer care quality and survival according to race and socioeconomic status, J. Natl. Cancer Inst., 105, 823, 10.1093/jnci/djt065 Peterson, 2015, The effect of neighborhood disadvantage on the racial disparity in ovarian cancer-specific survival in a large hospital-based study in cook county, illinois, Front. Public Health, 3, 8, 10.3389/fpubh.2015.00008 Brewer, 2015, The influence of neighborhood socioeconomic status and race on survival from ovarian cancer: a population-based analysis of Cook County, Illinois, Ann. Epidemiol., 25, 556, 10.1016/j.annepidem.2015.03.021 Terplan, 2012, Have racial disparities in ovarian cancer increased over time? An analysis of SEER data, Gynecol. Oncol., 125, 19, 10.1016/j.ygyno.2011.11.025 Bristow, 2015, Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines, Obstet. Gynecol., 125, 833, 10.1097/AOG.0000000000000643 Fuh, 2015, Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States, Gynecol. Oncol., 136, 491, 10.1016/j.ygyno.2014.10.009 Jacobsen, 1993, Reproductive factors and survival from ovarian cancer, Int. J. Cancer, 54, 904, 10.1002/ijc.2910540605 Herman-Giddens, 1997, Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network, Pediatrics, 99, 505, 10.1542/peds.99.4.505 Nagle, 2008, The influence of reproductive and hormonal factors on ovarian cancer survival, Int. J. Gynecol. Cancer, 18, 407, 10.1111/j.1525-1438.2007.01031.x Besevic, 2015, Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study, Br. J. Cancer, 113, 1622, 10.1038/bjc.2015.377 Mascarenhas, 2006, Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival, Int. J. Cancer, 119, 2907, 10.1002/ijc.22218 Yang, 2008, Predictors of ovarian cancer survival: a population-based prospective study in Sweden, Int. J. Cancer, 123, 672, 10.1002/ijc.23429 Jatoi, 2016, Clinical and emergent biomarkers and their relationship to the prognosis of ovarian cancer, Oncology, 10.1159/000442710 Poole, 2013, Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness, Cancer Epidemiol. Biomark. Prev., 22, 429, 10.1158/1055-9965.EPI-12-1183-T Yang, 2016, The association between endometriosis and survival outcomes of ovarian cancer: evidence-based on a meta-analysis, Niger. J. Clin. Pract., 18, 577, 10.4103/1119-3077.158941 Wang, 2013, Prognostic analysis of endometrioid epithelial ovarian cancer with or without endometriosis: a 12-year cohort study of Chinese patients, Am. J. Obstet. Gynecol., 209, 241, 10.1016/j.ajog.2013.05.032 McMeekin, 1995, Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis, Gynecol. Oncol., 59, 81, 10.1006/gyno.1995.1271 Katagiri, 2012, Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma, Mod. Pathol., 25, 282, 10.1038/modpathol.2011.161 Komiyama, 1999, Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation, Gynecol. Oncol., 72, 342, 10.1006/gyno.1998.5284 Orezzoli, 2008, Prognostic implication of endometriosis in clear cell carcinoma of the ovary, Gynecol. Oncol., 110, 336, 10.1016/j.ygyno.2008.05.025 Robbins, 2009, Influence of reproductive factors on mortality after epithelial ovarian cancer diagnosis, Cancer Epidemiol. Biomark. Prev., 18, 2035, 10.1158/1055-9965.EPI-09-0156 Zhang, 2012, Tubal ligation and survival of ovarian cancer patients, J. Obstet. Gynaecol. Res., 38, 40, 10.1111/j.1447-0756.2011.01683.x Li, 2015, Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis, Gynecol. Oncol., 139, 355, 10.1016/j.ygyno.2015.07.109 Eeles, 2015, Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial, J. Clin. Oncol., 33, 4138, 10.1200/JCO.2015.60.9719 Au-Yeung, 2014, Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS), Gynecol. Oncol., 133, 16, 10.1016/j.ygyno.2014.01.030 Bandera, 2015, Impact of chemotherapy dosing on ovarian cancer survival according to body mass index, JAMA Oncol., 1, 737, 10.1001/jamaoncol.2015.1796 Bae, 2014, Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis, J. Ovarian Res., 7, 41, 10.1186/1757-2215-7-41 Bandera, 2009, Nutritional factors in ovarian cancer survival, Nutr. Cancer, 61, 580, 10.1080/01635580902825670 McTiernan, 2010, Weight, physical activity, diet, and prognosis in breast and gynecologic cancers, J. Clin. Oncol., 28, 4074, 10.1200/JCO.2010.27.9752 Protani, 2012, Obesity and ovarian cancer survival: a systematic review and meta-analysis, Cancer Prev. Res. (Phila.), 5, 901, 10.1158/1940-6207.CAPR-12-0048 Nagle, 2015, Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium, Br. J. Cancer, 113, 817, 10.1038/bjc.2015.245 Zhou, 2011, Pre- and post-diagnosis body mass index, weight change, and ovarian cancer mortality, Gynecol. Oncol., 120, 209, 10.1016/j.ygyno.2010.10.035 Nagle, 2003, Dietary influences on survival after ovarian cancer, Int. J. Cancer, 106, 264, 10.1002/ijc.11204 Dolecek, 2010, Prediagnosis food patterns are associated with length of survival from epithelial ovarian cancer, J. Am. Diet. Assoc., 110, 369, 10.1016/j.jada.2009.11.014 Thomson, 2014, Diet quality and survival after ovarian cancer: results from the Women's Health Initiative, J. Natl. Cancer Inst., 106, 10.1093/jnci/dju314 Dixon, 2014, Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival, Gynecol. Oncol., 132, 566, 10.1016/j.ygyno.2013.12.025 Zhang, 2004, Green tea consumption enhances survival of epithelial ovarian cancer, Int. J. Cancer, 112, 465, 10.1002/ijc.20456 Cannioto, 2015, Epithelial ovarian cancer and recreational physical activity: a review of the epidemiological literature and implications for exercise prescription, Gynecol. Oncol., 137, 559, 10.1016/j.ygyno.2015.03.016 Moorman, 2011, Recreational physical activity and ovarian cancer risk and survival, Ann. Epidemiol., 21, 178, 10.1016/j.annepidem.2010.10.014 Kjaerbye-Thygesen, 2006, Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer, Cancer Epidemiol. Biomark. Prev., 15, 798, 10.1158/1055-9965.EPI-05-0897 Nagle, 2006, Cigarette smoking and survival after ovarian cancer diagnosis, Cancer Epidemiol. Biomark. Prev., 15, 2557, 10.1158/1055-9965.EPI-06-0592 Kelemen, 2016, Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer, Gynecol. Oncol., 140, 124, 10.1016/j.ygyno.2015.11.008